4,781 results match your criteria Am. J. Clin. Oncol.[Journal]


Recent Trends and Overall Survival of Young Versus Older Adults With Stage II to III Rectal Cancer Treated With and Without Surgery in the United States, 2010-2015.

Am J Clin Oncol 2020 Jul 7. Epub 2020 Jul 7.

Departments of Radiation Oncology.

Background: The omission of surgery via nonoperative management (NOM) for rectal cancer may be increasing, and this strategy could be particularly attractive for younger patients, whose incidence of rectal cancer has been rising. We sought to assess trends in NOM in young (younger than 55 y) versus older adult (55 y and older) rectal cancer cohorts.

Methods: The National Cancer Database was used to identify patients diagnosed with stage II to III rectal cancer between 2010 and 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000733DOI Listing

Radiotherapy for Adult Soft Tissue Sarcomas of the Head and Neck.

Am J Clin Oncol 2020 Jun 30. Epub 2020 Jun 30.

Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL.

Objective: Surgery followed by postoperative radiation therapy (RT) is the standard of care for soft tissue sarcomas (STS) of the head and neck that are high grade or have close or positive margins.

Methods: The authors retrospectively reviewed adult patients with head and neck STS treated with RT at a single institution between 1981 and 2017. All patients who were 19 years and older with STS of the head and neck-excluding rhabdomyosarcoma, angiosarcoma, and Ewing tumors-were included in this study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000729DOI Listing

Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry.

Am J Clin Oncol 2020 Jun 26. Epub 2020 Jun 26.

Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam.

Objective: By using the Korean Pancreatic Cancer (K-PaC) registry, we compared the clinical outcomes of FOLFIRINOX (FFX) and gemcitabine plus nab-paclitaxel (GNP) in patients with metastatic pancreatic cancer (MPC).

Methods: We constructed a web-based database of 3748 anonymized patients diagnosed with pancreatic ductal adenocarcinoma. MPC patients who received first-line FFX or GNP were enrolled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000730DOI Listing

Survivors' Perceptions of Quality of Colorectal Cancer Care by Sexual Orientation.

Am J Clin Oncol 2020 Jun 26. Epub 2020 Jun 26.

Harvard Medical School.

Objective: The objective of this study was to assess sexual minority and heterosexual survivors' perceived quality of cancer care and identify demographic, clinical, and psychosocial characteristics associated with patient-centered quality of care.

Materials And Methods: Four cancer registries provided data on 17,855 individuals who were diagnosed with stage I, II, or III colorectal cancer an average of 3 years prior and resided in predetermined diverse geographic areas. A questionnaire, which queried about sexual orientation and other eligibility criteria was mailed to all cancer survivors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000732DOI Listing

Comparison of Radiation Treatment Volumes for Borderline Resectable Pancreatic Cancer in Contemporary Clinical Trials.

Am J Clin Oncol 2020 Jun 19. Epub 2020 Jun 19.

University of Cincinnati Medical Center, Cincinnati, OH.

Objectives: Optimal radiation target volumes for neoadjuvant therapy in patients with borderline resectable pancreatic cancer (BRPCa) are undefined. Most local recurrences are near the celiac axis and superior mesenteric artery. Methods for generating radiation target volumes include symmetric expansion around the tumor or a customized vascular based approach. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000726DOI Listing

Alzheimer Gene BIN1 may Simultaneously Influence Dementia Risk and Androgen Deprivation Therapy Dosage in Prostate Cancer.

Am J Clin Oncol 2020 Jun 19. Epub 2020 Jun 19.

Severn Health Solutions, Severna Park, MD.

Background: Androgen deprivation therapy (ADT) is extensively used in prostate cancer. Yet the risk of impaired cognition or Alzheimer disease (AD) in men with prostate cancer receiving ADT is uncertain. Some studies of prostate cancer and ADT suggest that the risk of AD is not increased. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000727DOI Listing

Effectiveness and Safety of Reirradiation With Stereotactic Ablative Radiotherapy of Lung Cancer After a First Course of Thoracic Radiation: A Meta-analysis.

Am J Clin Oncol 2020 Jun 16. Epub 2020 Jun 16.

Faculdade de Medicina de Ribeirão Preto, Ribeirão Preto.

Objective: The effectiveness and safety of reirradiation with stereotactic ablative radiotherapy (re-SABR) in patients with recurrence after a previous course of radiation are limited to small series. We carried out a meta-analysis to summarize existing data and identify trends in overall survival (OS), local control (LC), and toxicity after re-SABR in patients with recurrence of lung cancer.

Materials And Methods: Eligible studies were identified on Medline, Embase, the Cochrane Library, and the proceedings of annual meetings through June 2019. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000709DOI Listing

Community-based Cancer Care Quality and Expertise in a COVID-19 Era and Beyond.

Authors:
Amit K Garg

Am J Clin Oncol 2020 Jun 5. Epub 2020 Jun 5.

MD Anderson Cancer Center, Radiation Oncology at the Jorgensen Cancer Center at Rust Hospital, Presbyterian Cancer Care, Albuquerque, NM.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000725DOI Listing

ACR-ASTRO Practice Parameter for Communication: Radiation Oncology.

Am J Clin Oncol 2020 Jun 5. Epub 2020 Jun 5.

Geisel School of Medicine at Dartmouth, Hanover, NH.

Aim/objectives/background: Timely, accurate, and effective communications are critical to quality in contemporary medical practices. Radiation oncology incorporates the science and technology of complex integrated radiation treatment delivery and the art of managing individual patients. Through written physical and/or electronic reports and direct communication, radiation oncologists convey critical information regarding patient care, services provided, and quality of care. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000707DOI Listing

Transformational Changes Between Non-Small Cell and Small Cell Lung Cancer-Biological and Clinical Relevance-A Review.

Am J Clin Oncol 2020 Jun 5. Epub 2020 Jun 5.

Department of Internal Medicine, Division of Hematology, Oncology, Blood and Marrow Transplantation, University of Iowa Hospitals and Clinics, Iowa City, IA.

During the course of therapy, patients with small cell lung cancer have been noted to develop transformation to non-small cell lung cancer and conversely, patients with non-small cell lung cancer have had transformation to small cell lung cancer or other non-small cell histologies. Transformation may occur after prior tyrosine kinase inhibitors, chemotherapy, immunotherapy or radiation therapy. These changes reflect on the overlapping biology of these cell types and the clinical need for re-biopsy at times of disease progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000720DOI Listing

Development of an Integer-based Risk Score to Predict 90-Day Mortality After Hepatectomy in Patients With Hepatocellular Carcinoma.

Am J Clin Oncol 2020 Jun 9. Epub 2020 Jun 9.

Departments of Epidemiology.

Background: The incidence of liver cancer has more than tripled since 1980. Hepatectomy represents the major curative treatment for liver cancer. The risk factors associated with 90-day mortality after hepatectomy are not well understood and there are currently no good prediction models for this outcome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000724DOI Listing

ACR-ACNM-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radium-223.

Am J Clin Oncol 2020 Jun 9. Epub 2020 Jun 9.

University of Michigan, Ann Arbor, MI.

Aim/objectives/background: The goal of therapy with unsealed radiopharmaceutical sources is to provide either cure or significant prolongation of disease-specific survival, and effective reduction and/or prevention of adverse disease-related symptoms or untoward events while minimizing treatment-associated side effects and complications. Radium-223 dichloride (radium-223) is an alpha particle-emitting isotope used for targeted bone therapy. This practice parameter is intended to guide appropriately trained and licensed physicians performing therapy with radium-223. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000702DOI Listing
June 2020
2.611 Impact Factor

Stereotactic Body Radiation Therapy for Intermediate-risk Prostate Cancer With VMAT and Real-time Electromagnetic Tracking: A Phase II Study.

Am J Clin Oncol 2020 Jun 2. Epub 2020 Jun 2.

Departments of Radiotherapy and Radiosurgery.

Objectives: Stereotactic body radiation treatment represents an intriguing therapeutic option for patients with early-stage prostate cancer. In this phase II study, stereotactic body radiation treatment was delivered by volumetric modulated arc therapy with flattening filter free beams and was gated using real-time electromagnetic transponder system to maximize precision of radiotherapy and, potentially, to reduce toxicities.

Materials And Methods: Patients affected by histologically proven prostate adenocarcinoma and National Comprehensive Cancer Network (NCCN) intermediate class of risk were enrolled in this phase II study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000721DOI Listing

Development and Validation of an Individualized Nomogram for Predicting Overall Survival in Patients With Typical Lung Carcinoid Tumors.

Am J Clin Oncol 2020 Jun 2. Epub 2020 Jun 2.

Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province.

Objective: We aim to develop and validate an effective nomogram prognostic model for patients with typical lung carcinoid tumors using a large patient cohort from the Surveillance, Epidemiology, and End Results (SEER) database.

Materials And Methods: Data from patients with typical lung carcinoid tumors between 2010 and 2015 were selected from the SEER database for retrospective analysis. Univariate and multivariate Cox analysis was performed to clarify independent prognostic factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000715DOI Listing
June 2020
2.611 Impact Factor

Medical Cannabis in Cancer Patients: A Survey of a Community Hematology Oncology Population.

Am J Clin Oncol 2020 Jun 2. Epub 2020 Jun 2.

Department of Hematology Oncology, Beaumont Health, Royal Oak, MI.

Objectives: Cancer patients are using medical cannabis (MC) to address symptoms; however, little data exist to guide clinicians when counseling patients. We seek to define the patterns of MC use among cancer patients, as well as efficacy and safety of MC.

Materials And Methods: Cancer patients attending oncology office visits at Beaumont Hospital, Michigan from July to December 2018 were anonymously surveyed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000718DOI Listing

Population-based Treatment Patterns and Outcomes for Stage III Non-Small Cell Lung Cancer Patients: A Real-world Evidence Study.

Am J Clin Oncol 2020 May 29. Epub 2020 May 29.

Alberta Health Services (AHS), Edmonton, AB.

Background: Most patients with stage III non-small cell lung cancer (NSCLC) develop metastases and succumb to their cancer. Approaches to the treatment of stage III disease can be highly variable. Understanding current treatment patterns can inform the optimal integration of emerging therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000716DOI Listing

Impact of Pain, Opioids, and the Mu-opioid Receptor on Progression and Survival in Patients With Newly Diagnosed Stage IV Pancreatic Cancer.

Am J Clin Oncol 2020 May 29. Epub 2020 May 29.

Cancer Research Center, HealthPartners/Park Nicollet.

Objectives: Pancreatic adenocarcinoma is frequently associated with pain requiring opioid therapy. Opioids, however, have been implicated in causing tumor progression, ultimately shortening survival. We examined the impact of pain, opioid use, and the mu-opioid receptor (MOP-R) expression in tumor tissue on progression-free survival and overall survival of patients with metastatic pancreatic cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000714DOI Listing

Prospective Translational Study Investigating Molecular PrEdictors of Resistance to First-Line PazopanIb in Metastatic reNal CEll Carcinoma (PIPELINE Study).

Am J Clin Oncol 2020 May 27. Epub 2020 May 27.

Department of Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan.

Objectives: Despite the initial clinical benefit, resistance to antiangiogenic therapies develops through the activation of alternative pathways. We measured plasma levels of circulating angiogenic factors to explore their predictive role in metastatic renal cell carcinoma (mRCC) patients treated with pazopanib.

Materials And Methods: mRCC patients receiving first-line pazopanib were prospectively enrolled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000719DOI Listing

The Effect of Systemic Chemotherapy on Survival in Patients With Localized, Regional, or Metastatic Adenocarcinoma of the Urinary Bladder.

Am J Clin Oncol 2020 May 27. Epub 2020 May 27.

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, Canada.

Objectives: To test the effect of systemic chemotherapy on cancer-specific mortality (CSM) in patients with adenocarcinoma of the urinary bladder (ADKUB).

Materials And Methods: Within the Surveillance, Epidemiology, and End Results registry (2004 to 2016), we identified patients with localized (T2-3N0M0), regional (T4N0M0/TanyN1-3M0), and metastatic (TanyNanyM1) ADKUB. Temporal trends, Kaplan-Meier plots, and multivariable Cox regression models were used before and after 1:1 propensity score matching and inverse probability of treatment weighting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000704DOI Listing

Sequencing Treatments for Cancer During the COVID-19 Pandemic.

Am J Clin Oncol 2020 07;43(7):457-458

Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000717DOI Listing

ACR-ASTRO Practice Parameter for Image-guided Radiation Therapy (IGRT).

Am J Clin Oncol 2020 Jul;43(7):459-468

American College of Radiology, Reston, VA.

Aim/objectives/background: The American College of Radiology (ACR) and the American Society for Radiation Oncology (ASTRO) have jointly developed the following practice parameter for image-guided radiation therapy (IGRT). IGRT is radiation therapy that employs imaging to maximize accuracy and precision throughout the entire process of treatment delivery with the goal of optimizing accuracy and reliability of radiation therapy to the target, while minimizing dose to normal tissues.

Methods: The ACR-ASTRO Practice Parameter for IGRT was revised according to the process described on the ACR website ("The Process for Developing ACR Practice Parameters and Technical Standards," www. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000697DOI Listing

ACR-ASTRO Practice Parameter for the Performance of Stereotactic Body Radiation Therapy.

Am J Clin Oncol 2020 May 12. Epub 2020 May 12.

Department of Radiation Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, NH.

Aim/objectives/background: To standardize the practice of stereotactic body radiation therapy (SBRT), the American College of Radiology (ACR) and the American Society for Radiation Oncology (ASTRO) cooperatively developed the practice parameter for SBRT. SBRT is a treatment technique that delivers radiation dose to a well-defined extracranial target in 5 fractions or less and usually employs a higher dose per fraction than used in conventional radiation.

Methods: The ACR-ASTRO Practice Parameter for the Performance of Stereotactic Body Radiation Therapy was revised according to the process described on the ACR website ("The Process for Developing ACR Practice Parameters and Technical Standards," www. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000706DOI Listing

Does the Interval Between Hysterectomy and Start of Adjuvant Radiation Treatment Influence Survival in Women With Endometrial Carcinoma?: A National Cancer Database analysis.

Am J Clin Oncol 2020 May 8. Epub 2020 May 8.

Departments of Radiation Oncology.

Objective: The objective of this study was to analyze the impact of the time interval (TI) between hysterectomy and initiation of adjuvant radiation treatment (ART) on overall survival (OS) among women with early stage endometrial carcinoma (EC) using the National Cancer Database (NCDB).

Materials And Methods: The NCDB was queried for women with the International Federation of Gynecology and Obstetrics (FIGO) stage I to II EC who underwent hysterectomy followed by ART. We examined the prognostic impact of TI on OS using the cutoff ≤8 or >8 weeks to initiate radiation treatment (RT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000713DOI Listing

Eligibility Criteria and Endpoints in Metastatic Renal Cell Carcinoma Trials.

Am J Clin Oncol 2020 May 8. Epub 2020 May 8.

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre.

Objectives: Treatments for metastatic renal cell carcinoma (mRCC) are often compared across trials, but trial eligibility criteria and endpoints differ. In an effort to better align trials, the Definition for the Assessment of Time to event Endpoints in CANcer trials (DATECAN) project published recommendations in 2015 to be used in mRCC clinical trial design. We analyzed mRCC trial criteria to determine if DATECAN's recommendations were followed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000705DOI Listing
May 2020
2.611 Impact Factor

"Was It Worth It?": A Pilot Study in Patient Perspectives on the Worthwhileness of Radiation Therapy.

Am J Clin Oncol 2020 May 1. Epub 2020 May 1.

Department of Radiation Medicine.

Objectives: Radiation therapy is a core oncologic treatment, but literature detailing patient satisfaction post-treatment is sparse. The authors conducted a pilot study to determine whether a simple survey would be feasible to administer and could elucidate factors predictive of satisfaction with radiotherapy.

Materials And Methods: Patients with cancer receiving radiotherapy in an academic radiation oncology department from 2014 to 2015 received a 4-item radiotherapy-focused version of the "Was It Worth It?" questionnaire (r-WIWI) on the last day of treatment and at the first follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000711DOI Listing

Analyzing the Time From Discovery to Definitive Surgical Therapy for Lung Cancer Based on Referral Patterns.

Am J Clin Oncol 2020 May 1. Epub 2020 May 1.

Department of Surgery, Division of Thoracic Surgery, The George Washington University Hospital, Washington, DC.

Objective: Surgery for early stage non-small cell lung cancer can be curative. A delay from diagnosis to surgery can lead to increased mortality. Our objective was to determine if referring patients to specialists before a thoracic surgeon caused a delay in definitive treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000710DOI Listing

Survival Benefit of Combination Chemotherapy in Elderly Patients With Metastatic Pancreatic Ductal Adenocarcinoma.

Am J Clin Oncol 2020 Apr 28. Epub 2020 Apr 28.

Division of Medical Oncology.

Objectives: Survival benefit of combination over single-agent chemotherapy for metastatic pancreatic ductal adenocarcinoma (PDAC) was demonstrated in younger patients in clinical trials. The authors aimed to evaluate whether this survival benefit of combination chemotherapy is present in elderly patients with metastatic PDAC.

Materials And Methods: The authors identified elderly patients (age 65 y or older) with stage IV PDAC and extracted available clinical information from a prospectively maintained institutional pancreatic cancer registry from 2007 to 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000708DOI Listing

The Population-based Impact of Adjuvant Chemotherapy on Outcomes in T2N0M0 Non-Small Cell Lung Cancer.

Am J Clin Oncol 2020 Jul;43(7):496-503

Department of Oncology, University of Calgary, Calgary, AB, Canada.

Objectives: The value of adjuvant chemotherapy in T2N0M0 non-small-cell lung cancer (NSCLC) is unclear. Some current guidelines suggest adjuvant chemotherapy be considered for patients with tumors ≥4 cm. Prior population-based evaluations lacked lung cancer-specific survival (LCSS) and health insurance status. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000694DOI Listing

Heterogenous Dose-escalated Prostate Stereotactic Body Radiation Therapy for All Risk Prostate Cancer: Quality of Life and Clinical Outcomes of an Institutional Pilot Study.

Am J Clin Oncol 2020 Jul;43(7):469-476

Department of Radiation Oncology, Taussig Cancer Institute.

Objectives: Previous prostate stereotactic body radiation therapy studies delivered uniform doses of 35 to 40 Gy/5 fx. Attempts at uniform dose escalation to 50 Gy caused high rates of gastrointestinal (GI) toxicity. We hypothesize that heterogeneous dose escalation to regions nonadjacent to sensitive structures (urethra, rectum, and bladder) is safe and efficacious. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000693DOI Listing

Capecitabine, Oxaliplatin, Irinotecan, and Bevacizumab Combination Followed by Pazopanib Plus Capecitabine Maintenance for High-Grade Gastrointestinal Neuroendocrine Carcinomas.

Am J Clin Oncol 2020 May;43(5):305-310

Unit of Clinical Pharmacology and Therapeutic Oncology, Department of Pharmacology, Medical School, National and Kapodistrian University of Athens.

Objectives: Gastrointestinal neuroendocrine carcinoma (NEC) is a lethal, uncommon, and understudied neoplasm. We present the efficacy and safety of first-line capecitabine (CP), oxaliplatin, irinotecan, and bevacizumab (CAPOXIRI-BEV) combination followed by pazopanib plus CP maintenance therapy in patients with advanced high-grade poorly differentiated gastrointestinal NEC.

Methods: This was a two-stage phase II study conducted at multiple institutions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000668DOI Listing
May 2020
2.611 Impact Factor

Stage-specific Conditional Survival Among Young (Age Below 50 y) Versus Older (Age 50 y and Above) Adults With Colorectal Cancer in the United States.

Am J Clin Oncol 2020 Jul;43(7):526-530

Departments of Radiation Oncology.

Background: Conditional survival (CS) is a relevant prognostic measure and may be particularly important for young adult patients with colorectal cancer (CRC), whose incidence is rising. We sought to compare CS among young versus older adults with CRC.

Methods: Patients diagnosed with CRC between 2004 and 2010 were identified from the Surveillance, Epidemiology, and End Results registry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000698DOI Listing

Characterizing Urban-Rural Differences in Colon Cancer Outcomes: A Population-based Analysis Based on Travel Distance to Cancer Center.

Am J Clin Oncol 2020 Jul;43(7):531-535

Department of Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.

Objective: We aimed to explore possible drivers for urban-rural disparities in colon cancer outcomes in a single-payer health care system where all patients had access to universal health care coverage.

Methods: Patients diagnosed with stage II/III colon cancer between 2004 and 2015 in Alberta, Canada were reviewed. On the basis of postal code, patients were categorized as living in urban, rural, or suburban areas based on travel distance to the cancer center. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000703DOI Listing
July 2020
2.611 Impact Factor

The Impact of the COVID-19 Pandemic on Cancer Patients.

Am J Clin Oncol 2020 06;43(6):452-455

Inpatient Pharmacist, The Specialty Hospital, Amman, Jordan.

In December 2019, a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused an outbreak of coronavirus disease 2019 (COVID-19). Severe complications have been reported to occur in 33% of patients with COVID-19 and include acute respiratory distress syndrome, acute renal failure, acute respiratory injury, septic shock, and severe pneumonia. Currently, there is no specific treatment or approved vaccine against COVID-19 and many clinical trials are currently investigating potential medications to treat COVID-19. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000712DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188063PMC

Tyrosine Kinase Inhibitors and the Relationship With Adherence, Costs, and Health Care Utilization in Commercially Insured Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study.

Am J Clin Oncol 2020 Jul;43(7):517-525

The University of Texas Health Science Center at Houston School of Public Health (HLP, CEB, WC, TMK), Houston, TX.

Objective: To examine the association among tyrosine kinase inhibitor (TKI) out-of-pocket costs, adherence, and health care costs and utilization in a large group of commercially insured patients with chronic myeloid leukemia (CML).

Materials And Methods: Patients with CML aged 18 to 64 years were identified using IBM MarketScan Commercial Database between April 1, 2011 and December 31, 2014. Patients were required to be continuously enrolled 3 months before and 12 months after TKI (imatinib, dasatinib, or nilotinib) initiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000700DOI Listing

A Prospective Study About Trastuzumab-induced Cardiotoxicity in HER2-positive Breast Cancer.

Am J Clin Oncol 2020 Jul;43(7):510-516

Departments of Medical Oncology.

Background: Trastuzumab improves therapeutic outcomes among patients with human epidermal growth factor receptor 2-positive breast cancer (BC). However, it is associated with a risk of treatment-induced cardiotoxicity. The aims of this study were to determine the frequency of trastuzumab-induced cardiotoxicity (TIC) in Tunisian patients, to study the effects of trastuzumab on cardiac biomarkers and echocardiographic parameters using the speckle tracking technique and to identify risk factors of occurrence of TIC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000699DOI Listing

A Phase 1 Study of SLC-0111, a Novel Inhibitor of Carbonic Anhydrase IX, in Patients With Advanced Solid Tumors.

Am J Clin Oncol 2020 Jul;43(7):484-490

BC Cancer.

Objectives: SLC-0111 is an ureido-substituted benzenesulfonamide small molecule inhibitor of carbonic anhydrase IX. The objectives of this first-in-human Phase 1 study were to determine the safety and tolerability of SLC-0111 in patients with advanced solid tumors and to establish the recommended Phase 2 dose for future clinical investigations.

Materials And Methods: Using a 3+3 design, dose escalation started at 500 mg oral daily dosing of SLC-0111 in cohort 1 and increased to 1000 and 2000 mg in cohorts 2 and 3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000691DOI Listing

Combination Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.

Am J Clin Oncol 2020 Jul;43(7):477-483

Department of Urology.

Introduction: Randomized clinical trials have shown combination therapy to be superior in progression-free survival (PFS) rates when compared with sunitinib alone. However, there have been no direct comparisons among the combination strategies making it unclear as to which may be the preferred option. We performed a network meta-analysis of the combination therapy (immune checkpoint inhibitor plus axitinib or bevacizumab) used in metastatic renal cell carcinoma (mRCC) and provided a rank order preference based on PFS, and adverse events (AEs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000695DOI Listing

Racial and Geographic Disparities in Endocrine Therapy Adherence Among Younger Breast Cancer Survivors.

Am J Clin Oncol 2020 Jul;43(7):504-509

The Cancer Survivorship Center, College of Nursing.

Objectives: African American (AA) women with breast cancer (BrCA) have higher mortality than any other race. Differential mortality has been attributed to nonadherence to endocrine therapy (ET). ET can lower the risk of dying by one third; yet 50% to 75% of all women are nonadherent to ET. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000696DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316591PMC

Neoadjuvant Phase II Trial of Chemoradiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer.

Am J Clin Oncol 2020 Jun;43(6):435-441

Division of Hematology and Medical Oncology.

Background: Pancreatic ductal adenocarcinoma is a largely incurable cancer. Surgical resection remains the only potential option for cure. Even in surgically resectable patients, only about 10% to 20% are long-term survivors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000688DOI Listing

Doxorubicin and Olaratumab Versus Doxorubicin, Ifosfamide, and Mesna for Treatment of Advanced Soft Tissue Sarcomas.

Am J Clin Oncol 2020 Jun;43(6):446-451

Division of Oncology, University of Washington.

Objective: We compared the outcomes in soft tissue sarcoma (STS) treated with olaratumab and doxorubicin (OD) versus doxorubicin, ifosfamide, and mesna (AIM) to assess whether OD could supersede AIM in STS therapy.

Methods: A single-institution, retrospective study of STS treated for advanced disease with OD or AIM in 2013 to 2017 was conducted. Demographic and clinical parameters were compared by Fisher's exact test. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000690DOI Listing

Brain Metastases From Gynecologic Malignancies: Prevalence and Management.

Am J Clin Oncol 2020 Jun;43(6):418-421

Division of Gynecologic Oncology.

Objective: The objective of this study was to investigate the prevalence, clinicopathologic characteristics, management, and outcomes of patients with brain metastasis (BM) from gynecologic malignancies in a large hospital-based database.

Materials And Methods: The National Cancer Database (NCDB) was accessed and patients with ovarian, uterine, or cervical cancer and BM were identified. We identified those who received radiation therapy (RT) as whole-brain radiation therapy (WBRT) or stereotactic radiosurgery (SRS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000689DOI Listing

Patterns of Care for Stage II-III Rectosigmoid Cancers in the United States, 2004-2015.

Am J Clin Oncol 2020 May;43(5):311-318

Departments of Radiation Oncology.

Objectives: Although current guidelines continue to recommend trimodality therapy for stage II to III rectal cancers, a lower incidence of local recurrence has been observed in patients with upper rectal tumors, including those in the rectosigmoid. In practice, patients with upper rectal tumors may not be receiving all 3 modalities of therapy. Patterns of care for patients with rectosigmoid cancers have not previously been described. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000674DOI Listing

Risk of Recurrence and 10-Year Outcomes in Surgically Treated Nonmelanoma Skin Cancer in Cardiac and Liver Transplant Recipients.

Am J Clin Oncol 2020 May;43(5):366-370

Departments of Radiation Oncology.

Objectives: To report long-term outcomes of nonmelanoma skin cancer (NMSC) in immunosuppressed cardiac and liver transplant recipients (CLTR).

Materials And Methods: The authors reviewed CLTR at the Mayo Clinic in Arizona from 1986 to 2013. Patient and tumor characteristics were recorded. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000677DOI Listing
May 2020
2.611 Impact Factor

Diagnostic Test Accuracy of Glasgow Prognostic Score as a Prognostic Factor for Renal Cell Carcinoma: A Meta-Analysis.

Am J Clin Oncol 2020 Jun;43(6):393-398

Department of Urology, Bundang Jesaeng General Hospital, Seongnam, Korea.

Objective: The objective of this study was to perform a meta-analysis of the diagnostic test accuracy of Glasgow Prognostic Score (GPS) as a prognostic factor for renal cell carcinoma (RCC).

Materials And Methods: Studies were retrieved from PubMed, Cochrane, and Embase databases, and we performed comprehensive searches to identify studies that evaluated the prognostic impact of pretreatment GPS in RCC patients. We assessed sensitivity, specificity, summary receiver operating characteristic curve, and area under the curve (AUC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000687DOI Listing

Outcomes and the Role of Primary Histology Following LINAC-based Stereotactic Radiation for Sarcoma Brain Metastases.

Am J Clin Oncol 2020 May;43(5):356-361

Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

Objectives: The brain is a rare site for sarcoma metastases. Sarcoma's radioresistance also makes standard whole-brain radiotherapy less appealing. We hypothesize that stereotactic radiation techniques (stereotactic radiosurgery [SRS]/stereotactic fractionated radiotherapy [FSRT]) may provide effective local control. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000675DOI Listing
May 2020
2.611 Impact Factor

Six-Week Interval Between Preoperative Radiation and Surgery Is Associated With Fewer Major Wound Complications in Soft Tissue Sarcoma.

Am J Clin Oncol 2020 Jul;43(7):491-495

Department of Orthopaedics, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH.

Objectives: A total of 30% to 40% of soft tissue sarcoma (STS) patients develop major wound complications (MWCs) after preoperative radiation (preRT). The optimal preRT-surgery interval and its association with MWCs is unknown. This study investigated whether a longer preRT-surgery interval is associated with fewer MWCs compared with historical controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000692DOI Listing

Association Between Metabolic Syndrome and Endometrial Cancer Survival in a SEER-Medicare Linked Database.

Am J Clin Oncol 2020 Jun;43(6):411-417

Departments of Radiation Oncology.

Background: Metabolic syndrome has previously been linked to increased risk of endometrial cancer. This study examines the association between metabolic syndrome and cancer-specific survival (CSS) in early stage and locoregionally advanced endometrial cancer.

Methods: The SEER-Medicare linked database was used to identify a cohort of patients with endometrial cancer between 1992 and 2011 who underwent hysterectomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000686DOI Listing

Outcomes and Utilization of Adjuvant Chemotherapy for Stage II Colon Cancer in the Oxaliplatin Period: A SEER-Medicare Analysis.

Am J Clin Oncol 2020 Jun;43(6):428-434

Department of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA.

Purpose: Previous SEER (Surveillance, Epidemiology, and End Results)-Medicare analyses have shown no definitive survival benefit for adjuvant chemotherapy (AC) with fluoropyrimidines. Impact of oxaliplatin-containing regimens for elderly stage II patients in real-world setting is unknown. We explored the utilization and outcome of AC after the Food and Drug Administration (FDA) approval of oxaliplatin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000684DOI Listing

Twitter: A Platform for Dissemination and Discussion of Scientific Papers in Radiation Oncology.

Am J Clin Oncol 2020 Jun;43(6):442-445

Department of Radiation Oncology, Centre Hospitalier de l'Université de Montréal (CHUM).

Objective: The objective of this study was to examine the correlation between Twitter mentions and the number of academic citations of radiation oncology articles.

Materials And Methods: We reviewed all 178 clinical manuscripts of the 2 most important radiation oncology journals and "Brachytherapy," and all clinical manuscripts relating to radiation oncology from the top 10 impact factor oncology journals, published between January and February 2018. We collected the record of citations utilizing Scopus and Google Scholar platforms and the number of times an article was tweeted about using the "Altmetric Bookmarklet. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000685DOI Listing
June 2020
2.611 Impact Factor